{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:04Z","timestamp":1792788364839,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Monash University","id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immune checkpoint inhibition is increasingly being investigated in localized mismatch repair-deficient or microsatellite instability-high (dMMR\/MSI-H) colon cancer, but evidence remains immature and often combined with broader cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed prospective interventional studies of neoadjuvant immune checkpoint inhibition in adults with localized, non-metastatic dMMR\/MSI-H colon cancer. The Ovid MEDLINE, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov databases and reference lists were searched to 12 June 2026. Studies were eligible when colon-specific pathological response outcomes were reported or extractable. Primary outcomes were pathological complete response (pCR) and major pathological response (MPR). Secondary outcomes included surgical feasibility, R0 resection, delay, morbidity, adverse events, recurrence, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six studies were included: NICHE, NICHE-2, NICHE-3, RESET-C, IMHOTEP, and IBI310\/sintilimab. pCR ranged from 44 to 78.4% and MPR from 57 to 95%, varying by regimen, denominator, and definition. NICHE-based dual-checkpoint studies reported pCR rates of 60\u201368% and MPR rates of 92\u201395%. Pembrolizumab-based studies reported pCR rates of 44\u201362.7%. The only randomized comparative study favored CTLA-4 plus programmed cell death protein-1 blockade over programmed cell death protein-1 blockade alone. Most patients proceeded to colectomy, with high R0 resection rates where reported. Severe treatment-related or immune-related adverse events occurred, including rare grade 5 events. Follow-up ranged from 8.1 to 26 months; recurrence was uncommon and survival outcomes immature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant immune checkpoint inhibition demonstrates substantial pathological activity and apparent surgical feasibility in selected localized dMMR\/MSI-H colon cancer. Longer follow-up and comparative trials are needed to define regimen, timing, patient selection, and durable oncological benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20430-9","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:03:02Z","timestamp":1786971782000},"page":"10641-10650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Immunotherapy in Localized dMMR\/MSI-H Colon Cancer: A Systematic Review of Pathological Response and Surgical Outcomes"],"prefix":"10.1245","volume":"33","author":[{"given":"Rathin","family":"Gosavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baxter","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanumant","family":"Chouhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thang Chien","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McMurrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"1","key":"20430_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0863.","journal-title":"Cancer Discov."},{"issue":"6349","key":"20430_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science."},{"issue":"23","key":"20430_CR3","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med."},{"issue":"10476","key":"20430_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andre","year":"2025","unstructured":"Andre T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405(10476):383\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(24)02848-4.","journal-title":"Lancet."},{"issue":"3","key":"20430_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa022289.","journal-title":"N Engl J Med."},{"issue":"20","key":"20430_CR6","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219\u201326. https:\/\/doi.org\/10.1200\/JCO.2009.27.1825.","journal-title":"J Clin Oncol."},{"issue":"25","key":"20430_CR7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","journal-title":"N Engl J Med."},{"issue":"23","key":"20430_CR8","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"A Cercek","year":"2025","unstructured":"Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med. 2025;392(23):2297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2404512.","journal-title":"N Engl J Med."},{"issue":"4","key":"20430_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566\u201376. https:\/\/doi.org\/10.1038\/s41591-020-0805-8.","journal-title":"Nat Med."},{"issue":"21","key":"20430_CR10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390(21):1949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med."},{"issue":"11","key":"20430_CR11","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","volume":"30","author":"PGM de Gooyer","year":"2024","unstructured":"de Gooyer PGM, Verschoor YL, van den Dungen LDW, Balduzzi S, Marsman HA, Geukes Foppen MH, et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med. 2024;30(11):3284\u201390. https:\/\/doi.org\/10.1038\/s41591-024-03250-w.","journal-title":"Nat Med."},{"issue":"18","key":"20430_CR12","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO-25-02274","volume":"44","author":"I Gogenur","year":"2026","unstructured":"Gogenur I, Justesen TF, Tarpgaard LS, Bulut M, Hansen TF, Jensen LH, et al. Neoadjuvant single-cycle pembrolizumab for stage I-III MMR-deficient colon cancer the RESET-C trial. J Clin Oncol. 2026;44(18):1687\u201396. https:\/\/doi.org\/10.1200\/JCO-25-02274.","journal-title":"J Clin Oncol."},{"issue":"16","key":"20430_CR13","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1200\/JCO-25-02169","volume":"44","author":"C de la Fouchardiere","year":"2026","unstructured":"de la Fouchardiere C, Zaanan A, de Montfort A, Cohen R, Le Sourd S, Tougeron D, et al. Efficacy of perioperative pembrolizumab in mismatch repair deficient\/microsatellite unstable localized colorectal cancers: results of the phase II trial IMHOTEP. J Clin Oncol. 2026;44(16):1520\u20138. https:\/\/doi.org\/10.1200\/JCO-25-02169.","journal-title":"J Clin Oncol."},{"issue":"10","key":"20430_CR14","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.ccell.2025.09.004","volume":"43","author":"F Wang","year":"2025","unstructured":"Wang F, Chen G, Qiu M, Ma J, Mo X, Liu H, et al. Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H\/dMMR colon cancer: a randomized phase 1b study. Cancer Cell. 2025;43(10):1958\u201367. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.004.","journal-title":"Cancer Cell."},{"issue":"6","key":"20430_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/DCR.0000000000003263","volume":"67","author":"A Loria","year":"2024","unstructured":"Loria A, Ammann AM, Olowokure OO, Paquette IM, Justiniano CF. Systematic review of neoadjuvant immunotherapy for mismatch repair deficient locally advanced colon cancer: an emerging strategy. Dis Colon Rectum. 2024;67(6):762\u201371. https:\/\/doi.org\/10.1097\/DCR.0000000000003263.","journal-title":"Dis Colon Rectum."},{"issue":"12","key":"20430_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","volume":"21","author":"CJM Williams","year":"2024","unstructured":"Williams CJM, Peddle AM, Kasi PM, Seligmann JF, Roxburgh CS, Middleton GW, et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. 2024;21(12):839\u201351. https:\/\/doi.org\/10.1038\/s41571-024-00943-6.","journal-title":"Nat Rev Clin Oncol."},{"issue":"11","key":"20430_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1097\/DCR.0000000000003927","volume":"68","author":"M Mui","year":"2025","unstructured":"Mui M, Kong JCH, Michael M, Ramsay R, Clemons NJ, Heriot AG. Role of neoadjuvant immune checkpoint inhibitors in locally advanced rectal cancer: a systematic review of currently available studies. Dis Colon Rectum. 2025;68(11):1265\u201374. https:\/\/doi.org\/10.1097\/DCR.0000000000003927.","journal-title":"Dis Colon Rectum."},{"issue":"8","key":"20430_CR18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541\u201352. https:\/\/doi.org\/10.1200\/JCO.22.00046.","journal-title":"J Clin Oncol."},{"issue":"8","key":"20430_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdy218.","journal-title":"Ann Oncol."},{"issue":"8","key":"20430_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1056\/NEJMc2409154","volume":"392","author":"B Rousseau","year":"2025","unstructured":"Rousseau B, White JR, Cercek A, Diaz LA Jr. The duration of immunotherapy for mismatch repair-deficient cancers. N Engl J Med. 2025;392(8):824\u20136. https:\/\/doi.org\/10.1056\/NEJMc2409154.","journal-title":"N Engl J Med."},{"issue":"12","key":"20430_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2507874","volume":"394","author":"FA Sinicrope","year":"2026","unstructured":"Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, et al. Atezolizumab plus FOLFOX for stage III mismatch repair-deficient colon cancer. N Engl J Med. 2026;394(12):1155\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2507874.","journal-title":"N Engl J Med."},{"issue":"2","key":"20430_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14796694.2025.2606910","volume":"22","author":"N Starling","year":"2026","unstructured":"Starling N, Elez E, Strickler JH, Benson A, Oki E, Mendez G, et al. A phase III study of perioperative dostarlimab in patients with dMMR\/MSI-H resectable colon cancer: AZUR-2 study design. Future Oncol. 2026;22(2):137\u201345. https:\/\/doi.org\/10.1080\/14796694.2025.2606910.","journal-title":"Future Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20430-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:24:15Z","timestamp":1792207455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20430-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20430"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20430-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}